Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRICC-C: Nintedanib + mFOLFOX6 in Advanced mCRC
NCT01362361Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Jun 2011
- Primary completion
- Jun 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (metastatic) (mCRC) comparing mFOLFOX6 + BIBF 1120 with mFOLFOX6 + Placebo (2 arms). Primary endpoint: Progression-Free Survival at 1 year. Started Jun 2011; status: completed.
02
Drugs
nintedanib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01362361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362361.